Ethic Inc. Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ethic Inc. grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 73.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,668 shares of the biopharmaceutical company's stock after acquiring an additional 4,509 shares during the period. Ethic Inc.'s holdings in Regeneron Pharmaceuticals were worth $7,599,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. OFI Invest Asset Management bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $28,000. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares during the last quarter. Avalon Trust Co acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter worth about $36,000. Crowley Wealth Management Inc. acquired a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $36,000. Finally, Private Wealth Management Group LLC grew its position in shares of Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 39 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Royal Bank of Canada decreased their target price on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. BMO Capital Markets cut their target price on Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective on the stock. StockNews.com cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Finally, TD Cowen lowered their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $890.60.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded up $8.40 during mid-day trading on Thursday, hitting $579.76. 802,161 shares of the company's stock were exchanged, compared to its average volume of 783,635. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a market cap of $63.38 billion, a price-to-earnings ratio of 15.17, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The stock's 50-day simple moving average is $605.64 and its 200-day simple moving average is $689.30. Regeneron Pharmaceuticals, Inc. has a 52 week low of $520.50 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $9.55 EPS. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.61%. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.